Is hyperprogressive disease a specific phenomenom of immunotherapy?

Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brambilla, Marta, Russo, Giuseppe Lo, Ferrara, Roberto, Manglaviti, Sara, Garassino, Marina Chiara, Occhipinti, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402399/
https://www.ncbi.nlm.nih.gov/pubmed/36046388
http://dx.doi.org/10.37349/etat.2020.00027
_version_ 1784773167780200448
author Brambilla, Marta
Russo, Giuseppe Lo
Ferrara, Roberto
Manglaviti, Sara
Garassino, Marina Chiara
Occhipinti, Mario
author_facet Brambilla, Marta
Russo, Giuseppe Lo
Ferrara, Roberto
Manglaviti, Sara
Garassino, Marina Chiara
Occhipinti, Mario
author_sort Brambilla, Marta
collection PubMed
description Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.
format Online
Article
Text
id pubmed-9402399
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94023992022-08-30 Is hyperprogressive disease a specific phenomenom of immunotherapy? Brambilla, Marta Russo, Giuseppe Lo Ferrara, Roberto Manglaviti, Sara Garassino, Marina Chiara Occhipinti, Mario Explor Target Antitumor Ther Letter to the Editor Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments. Open Exploration 2020 2020-12-28 /pmc/articles/PMC9402399/ /pubmed/36046388 http://dx.doi.org/10.37349/etat.2020.00027 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Brambilla, Marta
Russo, Giuseppe Lo
Ferrara, Roberto
Manglaviti, Sara
Garassino, Marina Chiara
Occhipinti, Mario
Is hyperprogressive disease a specific phenomenom of immunotherapy?
title Is hyperprogressive disease a specific phenomenom of immunotherapy?
title_full Is hyperprogressive disease a specific phenomenom of immunotherapy?
title_fullStr Is hyperprogressive disease a specific phenomenom of immunotherapy?
title_full_unstemmed Is hyperprogressive disease a specific phenomenom of immunotherapy?
title_short Is hyperprogressive disease a specific phenomenom of immunotherapy?
title_sort is hyperprogressive disease a specific phenomenom of immunotherapy?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402399/
https://www.ncbi.nlm.nih.gov/pubmed/36046388
http://dx.doi.org/10.37349/etat.2020.00027
work_keys_str_mv AT brambillamarta ishyperprogressivediseaseaspecificphenomenomofimmunotherapy
AT russogiuseppelo ishyperprogressivediseaseaspecificphenomenomofimmunotherapy
AT ferrararoberto ishyperprogressivediseaseaspecificphenomenomofimmunotherapy
AT manglavitisara ishyperprogressivediseaseaspecificphenomenomofimmunotherapy
AT garassinomarinachiara ishyperprogressivediseaseaspecificphenomenomofimmunotherapy
AT occhipintimario ishyperprogressivediseaseaspecificphenomenomofimmunotherapy

Ejemplares similares